other material
confidence high
sentiment neutral
materiality 0.60
AlloVir shareholders approve reverse stock split ratio range 1:15–1:35; board to set exact ratio
Kalaris Therapeutics, Inc.
- 96,216,120 votes for, 12,082,172 against, 303,036 abstain; adjournment not needed.
- Reverse split ratio of any whole number between 1:15 and 1:35, effective before Jan 10, 2026.
- Board will determine exact ratio and timing without further shareholder approval.
- Split is in connection with proposed merger with Kalaris Therapeutics, Inc.